Development of a New Drug Delivery System from HELA-Derived Exosomes and the Effect of Docetaxel-Loaded Exosomes on Mitochondrial Apoptosis

Cenik, Melike; Abas, Burçin İrem; Kocabiyik, Bilge; Demirbolat, Gülen Melike; Çevik, Özge

doi:10.1007/s12247-021-09566-1

Cited by 11 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, we used exosomes as a different carrier by loading the exosomes we isolated from Hela cells with docetaxel. We showed that re-administration of modified exosomes to the same Hela cells induces cell death [ 39 ]. In a study of exosomes developing biomimetic nanoparticles without losing the integrity of proteins, they first developed doxorubicin (DOX) loaded silicon nanoparticles.…”

Section: Discussionmentioning

confidence: 99%

Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel

2022

Self Cite

View full text Add to dashboard Cite

Mesenchymal stem cells can be obtained and multiplied from various sources and have a very high capacity to release exosomes. Exosomes are nano-sized extracellular vesicles containing biological signaling molecules. This study aimed to determine the effect of MSC-derived exosomes as a drug delivery system for paclitaxel in cervical cancer cells. In this study, human MSC were isolated from wharton jelly of umbilical cord tissue (WJ-MSC), and cells were characterized by CD44, CD90, CD105, and CD34 staining. Exosomes were released in WJ-MSC cells with serum-starved conditions for 48 hours, and particle sizes and structures were examined with zeta-sizer and TEM. In addition, exosomes CD9, CD63, and CD81 markers were checked by western blot. Paclitaxel was loaded into exosomes (Exo-PAC) by electroporation and then incubated with Hela cervical cancer cells for 24 hours. TGF-β, SMAD, Snail, Slug, β-catenin, Notch, Caspase-3, Caspase-9, Bax, Bcl-2 protein and gene expression levels were analyzed in Hela cells. As a result, low concentration Exo-PAC induced apoptosis, and suppressed epithelial-mesenchymal transition proteins in Hela cells. In this study, it has been demonstrated that WJ-MSCs can be used as drug delivery systems for cervical cancer if exosomes are produced scalably in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel

2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, the Dexo vaccine promoted E7 antigeninduced immune responses in the splenocytes of immunized mice. Furthermore, Cenik et al (2022) demonstrated that docetaxel-loaded exosomes (Exo-Doc) could reduce docetaxel dosage and toxicity. At the same time, they induced mitochondrial apoptosis in HeLa cells and increased the metastasis of resistant cells.…”

Section: Exosomesmentioning

confidence: 99%

Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy

et al. 2022

View full text Add to dashboard Cite

Immunotherapy is an emerging method for the treatment of cervical cancer and is more effective than surgery and radiotherapy, especially for recurrent cervical cancer. However, immunotherapy is limited by adverse effects in clinical practice. In recent years, nanotechnology has been widely used for tumor diagnosis, drug delivery, and targeted therapy. In the setting of cervical cancer, nanotechnology can be used to actively or passively target immunotherapeutic agents to tumor sites, thereby enhancing local drug delivery, reducing drug adverse effects, achieving immunomodulation, improving the tumor immune microenvironment, and optimizing treatment efficacy. In this review, we highlight the current status of therapeutic vaccines and adoptive cell therapy in cervical cancer immunotherapy, as well as the application of lipid carriers, polymeric nanoparticles, inorganic nanoparticles, and exosomes in this context.

show abstract

“…Neuroprotection and ischemia-reperfusion injury treatment [260] Inhibit the phosphorylation of Tau protein [261] Exosomes from mesenchymal stem cells Attenuate the progression of osteoarthritis [262] EVs from HEK293 cells Myocardial infarction treatment [263] Exosomes from bone marrow-derived mesenchymal stem cells Cerebral ischemia treatment [264] Exosomes from HEK293 cells Curcumin and RAGE-binding peptide Acute lung injury treatment [265] EVs from smooth muscle cells Cystatin C Protection and healing of the nervous system in different neurotoxic conditions [266] Exosomes from lung cancer Docetaxel Non-small cell lung cancer treatment [267] Exosomes from cervical cancer Cervical cancer treatment [268] Exosomes from blood samples Dopamine Parkinson's disease treatment [269] EVs from macrophages Doxorubicin Metastatic ovarian cancer treatment [270] Exosomes from mesenchymal stem cells Colorectal cancer treatment [271] Exosomes from human glioma Glioma treatment [272] Milk-derived exosomes Cancer treatment [273] Exosomes from HEK293 cells Cancer treatment [274] Exosomes from bone marrow-derived mesenchymal stem cells Osteosarcoma treatment [275] Exosomes from colon cancer Colorectal cancer treatment [276] Exosomes from human breast and ovarian cancer Breast and ovarian cancer treatment [277] Exosomes from macrophages Edaravone Permanent middle cerebral artery occlusion treatment [278] Exosomes from human fetal lung fibroblasts Erastin Triple-negative breast cancer therapy [279] Exosomes from pancreatic cells Gemcitabine Pancreatic cancer treatment [280] EVs from human plasma Imperialine Non-small cell lung cancer treatment [281] EVs from human umbilical vascular endothelial cells…”

Section: Curcuminmentioning

confidence: 99%

Lipid-Based Nanovesicular Drug Delivery Systems

et al. 2021

View full text Add to dashboard Cite

In designing a new drug, considering the preferred route of administration, various requirements must be fulfilled. Active molecules pharmacokinetics should be reliable with a valuable drug profile as well as well-tolerated. Over the past 20 years, nanotechnologies have provided alternative and complementary solutions to those of an exclusively pharmaceutical chemical nature since scientists and clinicians invested in the optimization of materials and methods capable of regulating effective drug delivery at the nanometer scale. Among the many drug delivery carriers, lipid nano vesicular ones successfully support clinical candidates approaching such problems as insolubility, biodegradation, and difficulty in overcoming the skin and biological barriers such as the blood–brain one. In this review, the authors discussed the structure, the biochemical composition, and the drug delivery applications of lipid nanovesicular carriers, namely, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes, phytosomes, catanionic vesicles, and extracellular vesicles.

show abstract

Development of a New Drug Delivery System from HELA-Derived Exosomes and the Effect of Docetaxel-Loaded Exosomes on Mitochondrial Apoptosis

Cited by 11 publications

References 38 publications

Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel

Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel

Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy

Lipid-Based Nanovesicular Drug Delivery Systems

Contact Info

Product

Resources

About